Tina Bhutani-Jacques, MD, MAS, FAAD

Learn how to personalize systemic psoriasis care, weigh comorbidities, and aim for rapid clearance to reduce heart and joint risks.

Learn how dermatologists tailor psoriasis treatment—topicals, phototherapy, pills or biologics—using shared decisions, severity and comorbidities.

Explore how cutting inflammation in psoriasis may lower heart risks, and why new oral TYK2 inhibitors could broaden treatment beyond injections.

Derm experts compare TYK2 pills with biologics for psoriasis—safety, speed, infections, and when combination therapy helps stubborn skin and joints.

Experts explain how deucravacitinib eases psoriasis itch fast, boosts quality of life, and why TB testing and boxed warnings matter.

New oral psoriasis therapy delivers biologic-level skin clearance in tough patients, with PASI 100 rising to 42% by week 24.

Psoriasis care shifts beyond skin: treat-to-target goals, heart risk reduction, and new oral TYK2 pills with strong safety data.

Discover how oral TYK2 inhibitors deliver targeted psoriasis control with strong safety data and biologic-like clearance, including insights on deucravacitinib and zasocitinib.

Expert dermatologists urge aggressive psoriasis control to prevent heart and joint risks, highlight unmet needs, and preview TYK2 inhibitors as a safer oral option.

Explore how TYK2 inhibitors reshape psoriasis care, as experts weigh comorbidities, infection screening, and treat-to-target goals to overcome real-world treatment hurdles.

Panelists discuss how the treatment landscape for psoriasis continues to evolve, with oral agents expected to play an expanding role alongside biologics. Ongoing innovation in TYK2 inhibition and PDE4 modulation may yield even more effective and tolerable options, reshaping patient expectations for convenience and control. Panelists discuss how integration of real-world data and head-to-head comparisons will clarify positioning of oral therapies across disease severities. Future directions include exploring combination strategies and earlier oral intervention to delay or reduce biologic use. Panelists discuss how continued advancement in oral therapy represents a broader shift toward personalized, accessible psoriasis care that empowers patients and supports sustained disease control.

Panelists discuss how practical factors such as dosing, monitoring, and patient preference shape optimal use of oral psoriasis therapies.

Panelists discuss how both oral agents exhibit reassuring long-term safety and tolerability that support continued use in diverse psoriasis populations.

Panelists discuss how deucravacitinib provides greater scalp and high-impact site clearance than apremilast, supporting more personalized psoriasis care.

Panelists discuss how clinical evidence shows deucravacitinib’s superior efficacy over apremilast while underscoring the need for individualized therapy selection.

Panelists discuss how clinical evidence shows deucravacitinib’s superior efficacy over apremilast while underscoring the need for individualized therapy selection.

Panelists discuss how deucravacitinib and apremilast act through distinct immune pathways that shape their efficacy, safety, and therapeutic roles.

Panelists discuss how oral psoriasis therapies enhance flexibility and patient-centered treatment options across varying disease severities.